OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.
The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.
The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $3M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Althea Gro... | altheagrou... |
| - | Helios Cap... | helioscapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2019 | Seed | $3M | - |
Mentions in press and media 4
| Date | Title | Description |
| 11.05.2020 | Seattle biotech startup OncoSenX raising more cash for cancer-fighting therapies | Biotech startup OncoSenX is raising more cash to help support its pipeline of therapeutics that aim to kill cancer cells based on their genetics. Its technology targets solid tumors based on a patented lipid nanoparticle gene delivery syste... |
| 11.07.2019 | Cancer Therapeutics Company OncoSenX Secures $3 Million | Late preclinical-stage company OncoSenX has raised $3 million in pre-seed funding to develop therapeutics for killing cancer cells OncoSenX — a late preclinical-stage company developing therapeutics for killing cancer cells based on their g... |
| 08.07.2019 | OncoSenX Raises $3M in Pre Seed Funding | OncoSenX, Inc., a Seattle, WA-based late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, raised $3m in pre-seed funding. The backers were not disclosed. The company intends to use the funds to... |
| 08.07.2019 | OncoSenX closes $3 million funding to accelerate the preclinical research of new class of cancer therapeutics | OncoSenX, a late preclinical-stage startup developing therapeutics to kill cancer cells based on their genetics, today announced it has raised $3 million in pre-seed funding to accelerate the preclinical research of new class of cancer ther... |